Meridian Bioscience ROA 2006-2018 | VIVO

Current and historical return on assets (ROA) values for Meridian Bioscience (VIVO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Meridian Bioscience ROA for the three months ending June 30, 2018 was 11.62%.
Meridian Bioscience Annual ROA
2017 8.63
2016 12.79
2015 19.39
2014 19.64
2013 21.52
2012 20.68
2011 17.26
2010 17.23
2009 21.00
2008 20.63
2007 20.14
2006 15.21
2005 11.43
Meridian Bioscience Quarterly ROA
Q3 2018 2.69
Q2 2018 2.08
Q1 2017 2.50
Q4 2017 2.29
Q3 2017 0.10
Q2 2017 3.70
Q1 2016 2.51
Q4 2016 2.18
Q3 2016 3.43
Q2 2016 3.52
Q1 2015 4.77
Q4 2015 4.62
Q3 2015 5.08
Q2 2015 5.65
Q1 2014 4.45
Q4 2014 4.63
Q3 2014 4.94
Q2 2014 5.78
Q1 2013 4.25
Q4 2013 5.18
Q3 2013 5.94
Q2 2013 6.18
Q1 2012 5.39
Q4 2012 5.31
Q3 2012 5.41
Q2 2012 6.08
Q1 2011 4.24
Q4 2011 4.32
Q3 2011 4.33
Q2 2011 4.62
Q1 2010 3.86
Q4 2010 3.44
Q3 2010 4.30
Q2 2010 3.93
Q1 2009 5.77
Q4 2009 5.73
Q3 2009 5.73
Q2 2009 4.98
Q1 2008 5.53
Q4 2008 5.25
Q3 2008 5.50
Q2 2008 5.19
Q1 2007 5.52
Q4 2007 4.86
Q3 2007 7.01
Q2 2007 4.84
Q1 2006 4.56
Q4 2006 3.97
Q3 2006 4.23
Q2 2006 4.31
Q1 2005 3.57
Q4 2005 3.47
Q3 2005 4.34
Q2 2005 4.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.642B $0.201B
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $132.148B 20.26
Abbott Laboratories (ABT) United States $121.136B 25.39
Stryker (SYK) United States $65.261B 25.22
Boston Scientific (BSX) United States $52.233B 27.17
Baxter (BAX) United States $41.336B 28.14
Zimmer Biomet Holdings (ZBH) United States $26.744B 17.18
ResMed (RMD) United States $16.242B 32.25
Smith & Nephew SNATS (SNN) United Kingdom $16.130B 0.00
Canopy Growth (CGC) Canada $11.376B 0.00
Perrigo (PRGO) Ireland $10.065B 14.28
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.065B 20.57
Insulet (PODD) United States $6.029B 0.00
Haemonetics (HAE) United States $5.767B 52.63
ICU Medical (ICUI) United States $5.434B 36.82
Neogen (NEOG) United States $4.634B 73.73
GW Pharmaceuticals (GWPH) United Kingdom $4.582B 0.00
Agios Pharmaceuticals (AGIO) United States $4.266B 0.00
Hutchison China MediTech (HCM) China $3.798B 0.00
NuVasive (NUVA) United States $3.542B 33.60
National Vision Holdings (EYE) United States $3.271B 72.23
Quidel (QDEL) United States $2.532B 51.87
NxStage Medical (NXTM) United States $1.847B 0.00
Phibro Animal Health (PAHC) United States $1.708B 24.31
AtriCure (ATRC) United States $1.247B 0.00
Cardiovascular Systems (CSII) United States $1.233B 735.80
Omeros (OMER) United States $1.216B 0.00
VAREX IMAGING (VREX) United States $1.138B 18.60
Owens & Minor (OMI) United States $1.069B 11.44
PetIQ (PETQ) United States $1.069B 34.97
Eagle Pharmaceuticals (EGRX) United States $1.015B 29.95
Cerus (CERS) United States $0.985B 0.00
Surmodics (SRDX) United States $0.972B 117.42
MacroGenics (MGNX) United States $0.938B 0.00
OraSure Technologies (OSUR) United States $0.938B 61.32
TG Therapeutics (TGTX) United States $0.745B 0.00
Insys Therapeutics (INSY) United States $0.679B 0.00
LeMaitre Vascular (LMAT) United States $0.667B 32.00
Lantheus Holdings (LNTH) United States $0.599B 18.63
Evolus (EOLS) United States $0.502B 0.00
NanoString Technologies (NSTG) United States $0.499B 0.00
Quanterix (QTRX) United States $0.427B 0.00
Cytosorbents (CTSO) United States $0.423B 0.00
Utah Medical Products (UTMD) United States $0.357B 22.97
Surface Oncology (SURF) United States $0.332B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Rockwell Medical (RMTI) United States $0.228B 0.00
Chimerix (CMRX) United States $0.191B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.172B 0.00
Fonar (FONR) United States $0.155B 7.73
Chembio Diagnostics (CEMI) United States $0.135B 0.00
Female Health (VERU) United States $0.099B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.085B 0.00
Trinity Biotech (TRIB) Ireland $0.082B 24.50
United-Guardian (UG) United States $0.076B 16.62
Neurotrope (NTRP) United States $0.066B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.049B 0.00
Capricor Therapeutics (CAPR) United States $0.033B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Akers Biosciences Inc (AKER) United States $0.024B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00